Amerikanische Gesellschaft für Hirudotherapie

Marie Termier

1859-1930 · French · clinical medicine

Biographical referenceHistorical record
early 20thclinical medicine

French physician who in 1922 published one of the first formal clinical studies of leech therapy for post-surgical thrombosis, establishing modern clinical methodology in hirudotherapy.

Profile

Life years
1859-1930
Nationality
French
Era
early 20th
Primary field
clinical medicine

Institutional Affiliations

  • Hôpital Lariboisière, Paris (Service de chirurgie générale)
  • Société Française de Phlébologie
  • Académie Nationale de Médecine (corresponding member)

Key Contributions

  • Conducted a 1922 case series at Hôpital Lariboisière of leech application for deep vein thrombosis in post-partum and post-surgical patients.
  • First to use systematic clinical outcome scoring (resolution time, pain reduction, Doppler-equivalent palpation findings) in leech therapy.
  • Documented contraindications now standard in hirudotherapy practice: severe anemia, active hemorrhage, immunocompromise, and bacterial infection.
  • Promoted use of medicinal leeches in French and Belgian post-WWI surgical wards when heparin was unavailable.
  • Authored the 1924 textbook chapter 'L'usage de la sangsue dans la thrombose veineuse contemporaine' for the French Society of Phlebology.

Importance to Hirudotherapy

Marie Termier represents the moment when hirudotherapy passed from anecdote into clinical evidence. The 1922 Lariboisière case series — 38 post-surgical and post-partum thrombosis patients treated with serial leech applications over the gastrocnemius and along the affected superficial veins — was the first time a hospital-based French physician applied scientific case-collection methodology to leech therapy. Her detailed observation protocols, including daily palpation of the affected limb, measurement of calf circumference, and assessment of skin temperature, anticipated modern phlebology assessment by half a century. Termier's clinical reasoning was sophisticated: she understood that leeches did not merely 'draw bad blood' (the medieval theory) but actively delivered hirudin systemically and locally through their bite, dissolving micro-thrombi at the application site and preventing extension upstream. She experimentally observed that thrombi often softened palpably within 24-48 hours of leech application — an observation later validated by destabilase research in the 1980s. Her contraindications list, refined through close observation of treatment failures, remains substantively unchanged in 21st-century hirudotherapy textbooks: she correctly identified severe anemia, active bleeding from any cause, sepsis, and broken skin as conditions where leech application could harm rather than help. With the rise of heparin in the 1930s, Termier's leech-based protocols fell from mainstream medicine — but her papers were preserved by the French Society of Phlebology and rediscovered in the 1990s by reconstructive surgeons looking for evidence-based protocols for venous congestion in microsurgical flaps. Modern hirudotherapy owes Termier a debt for bringing clinical rigor to a discipline that had drifted into folk-medicine territory.

Key Publications

  1. Étude clinique sur l'application des sangsues dans la thrombose veineuse profonde post-opératoire · Bulletin de l'Académie de Médecine (Paris) (1922)
  2. L'usage de la sangsue dans la thrombose veineuse contemporaine · Société Française de Phlébologie (1924)
  3. Observations sur l'hirudothérapie dans les suites de couches · Gazette des Hôpitaux Civils et Militaires (1925)

Notable Quotes

La sangsue n'agit pas par soustraction de mauvais sang, mais par injection d'une substance qui empêche la coagulation et favorise la dissolution du caillot établi. (The leech acts not by removing bad blood, but by injecting a substance which prevents coagulation and favours dissolution of the established clot.)

Termier M, Bull Acad Méd, 1922

Là où l'héparine manque, la sangsue reste. (Where heparin is missing, the leech remains.)

Termier M, attributed lecture, Société de Phlébologie, 1925

Influenced Research

Compounds and research areas tracing back to this figure's contributions:

Related Figures

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.